Ranger Biotechnologies A/S: Financial statements 2013
CVR: 32280404
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
Ranger Biotechnologies A/S (CVR 32280404) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK -699,000 and a net result of DKK -1,130,000 compared with DKK -1,246,409 the year before. Equity in the 2013 report amounted to DKK 6,015,000. The solvency ratio was 95.2%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -699,000
- Profit/Loss
- DKK -1,130,000
- Equity
- DKK 6,015,000
- Total Assets
- DKK 6,315,000
- Employees
- 1
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
Ranger Biotechnologies A/S has published its annual report for 2012. Gross profit came to DKK -755,567, and the net result was DKK -1,246,409.
As of May 31, 2013, Ole Bitsch-Jensen has left the board of directors of Ranger Biotechnologies A/S.
About Ranger Biotechnologies A/S
Ranger Biotechnologies A/S is a Danish company of the type Aktieselskab based in Odense SØ, founded in 2009. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named MIRRX THERAPEUTICS A/S and MIRX THERAPEUTICS A/S. The management consists of Hans Thorleif Møller. The board consists of Christina Møller Udesen (chair), Hans Thorleif Møller, Kasper Tvede Larsen and Søren Tvede Larsen. The company is owned by QUERDENKER ApS and Outlate Holding ApS. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK -409,444 and a net result of DKK -843,419 compared with DKK -1,138,092 the year before. Equity in the 2025 report amounted to DKK 711,273.